Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study

Respiratory Research

Judith L Black²  Gregory G King⁴  Sam Lim¹  Janette K Burgess²  Brian GG Oliver²  Melissa Baraket³ 

[1] ANZAC Research Institute, Sydney, NSW, Australia;Sydney Medical School, University of Sydney, Sydney, NSW, Australia;Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia;Department of Respiratory Medicine, Royal North Shore Hospital, Sydney, NSW, Australia

关键词: airway remodeling;    airway inflammation;    alveolar macrophage;    airway hyperresponsiveness;    corticosteroids;    asthma;   

Others  :  796750
DOI  :  10.1186/1465-9921-13-11

 received in 2011-08-29, accepted in 2012-02-02,  发布年份 2012

【 摘 要 】

Background

While most of the clinical benefits of inhaled corticosteroid (ICS) therapy may occur at low doses, results of dose-ranging studies are inconsistent. Although symptom/lung function response to low and high dose ICS medication is comparable, it is uncertain whether low dose ICSs are as effective as high dose in the treatment of inflammation and remodeling.

Methods

22 mild or moderate asthmatic adult subjects (corticosteroid free for > 2 months) participated in a randomized, parallel group study to compare effects of fluticasone propionate (FP) 200 mcg/day and 1000 mcg/day. Alveolar macrophage (AM)-derived cytokines and basement membrane thickness (BMT) were measured at baseline and after 7 weeks treatment while symptoms, spirometry, exhaled nitric oxide (eNO) and airway hyperresponsiveness (AHR) to mannitol at baseline and 6 weeks.

Results

FP improved spirometry, eNO, symptoms and AHR with no difference between low and high dose FP. Both high and low dose FP reduced GM-CSF, TNF-alpha and IL-1ra, with no change in BMT and with no differences between low and high dose FP.

Conclusions

200 μg/day of FP was as effective as 1000 μg/day in improving asthma control, airway inflammation, lung function and AHR in adults in the short term. Future studies should examine potential differential effects between low and high dose combination therapy (ICS/long acting beta agonist) on inflammation and airway remodeling over longer treatment periods.

【 授权许可】

   
2012 Baraket et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates C: Inhaled fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, (3):CD003534.
• [2]Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL: A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002, 24(1):1-20.
• [3]Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, et al.: Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998, 101(4 Pt 1):457-63.
• [4]Pedersen S, Hansen OR: Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995, 95(1 Pt 1):29-33.
• [5]Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, et al.: Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998, 132(6):976-82.
• [6]Masoli M, Weatherall M, Holt S, Beasley R: Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004, 59(1):16-20.
• [7]Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, et al.: Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J 2002, 20(3):601-8.
• [8]Chanez P, Karlstrom R, Godard P: High or standard initial dose of budesonide to control mild-to-moderate asthma? Eur Respir J 2001, 17(5):856-62.
• [9]Tukiainen H, Taivainen A, Majander R, Poussa T, Svahn T, Puolijoki H, et al.: Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir Med 2000, 94(7):678-83.
• [10]Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 109(3):410-8.
• [11]Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R: Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Bmj 2001, 323(7307):253-6.
• [12]Taylor DA, Jensen MW, Kanabar V, Engelstatter R, Steinijans VW, Barnes PJ, et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. American Journal of Respiratory & Critical Care Medicine 1999, 160(1):237-43.
• [13]Gershman NH, Wong HH, Liu JT, Fahy JV: Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000, 15(1):11-8.
• [14]Swystun VA, Bhagat R, Kalra S, Jennings B, Cockcroft DW: Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol 1998, 102(3):363-7.
• [15]Jatakanon A, Kharitonov S, Lim S, Barnes PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999, 54(2):108-14.
• [16]Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A, Cantini L: Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics. Allergy 2003, 58(10):1018-22.
• [17]Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002, 57(10):889-96.
• [18]Visser MJ, van der Veer E, Postma DS, Arends LR, de Vries TW, Brand PL, et al.: Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J 2004, 24(3):420-5.
• [19]Donnelly R, Williams KM, Baker AB, Badcock CA, Day RO, Seale JP: Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. American Journal of Respiratory & Critical Care Medicine 1997, 156(6):1746-51.
• [20]Nielsen LP, Dahl R: Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 2000, 162(6):2053-7.
• [21]Visser MJ, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PL: One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height. Am J Respir Crit Care Med 2001, 164(11):2073-7.
• [22]Wilson AM, McFarlane LC, Lipworth BJ: Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. American Journal of Respiratory & Critical Care Medicine 1997, 156(4 Pt 1):1274-7.
• [23]Wilson AM, Sims EJ, Lipworth BJ: Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology 1999, 50(3):329-35.
• [24]Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ: Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology 2001, 52(1):93-5.
• [25]Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Archives of Internal Medicine 1999, 159(9):941-55.
• [26]Masoli M, Holt S, Weatherall M, Beasley R: Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004, 23(4):552-8.
• [27]Nathan RA, Li JT, Finn A, Jones R, Payne JE, Wolford JP, et al.: A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000, 118(2):296-302.
• [28]Raphael GD, Lanier RQ, Baker J, Edwards L, Rickard K, Lincourt WR: A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol 1999, 103(5 Pt 1):796-803.
• [29]Wolfe JD, Selner JC, Mendelson LM, Hampel F Jr, Schaberg A: Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther 1996, 18(4):635-46.
• [30]Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P, et al.: A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993, 104(5):1352-8.
• [31]Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, et al.: Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000, 29(6):415-23.
• [32]Powell N, Till SJ, Kay AB, Corrigan CJ: The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3 and GM-CSF mRNA and protein. Clin Exp Allergy 2001, 31(1):69-76.
• [33]Ek A, Larsson K, Siljerud S, Palmberg L: Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999, 54(7):691-9.
• [34]Joseph M, Tonnel AB, Torpier G, Capron A, Arnoux B, Benveniste J: Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest 1983, 71(2):221-30.
• [35]Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph M, et al.: Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J Allergy Clin Immunol 1999, 103(2 Pt 1):289-97.
• [36]Viksman MY, Bochner BS, Peebles RS, Schleimer RP, Liu MC: Expression of activation markers on alveolar macrophages in allergic asthmatics after endobronchial or whole-lung allergen challenge. Clin Immunol 2002, 104(1):77-85.
• [37]Soloperto M, Mattoso VL, Fasoli A, Mattoli S: A bronchial epithelial cell-derived factor in asthma that promotes eosinophil activation and survival as GM-CSF. Am J Physiol 1991, 260(6 Pt 1):L530-8.
• [38]Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326(5):298-304.
• [39]Ackerman V, Marini M, Vittori E, Bellini A, Vassali G, Mattoli S: Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients. Relationship to atopic status, symptoms, and level of airway hyperresponsiveness. Chest 1994, 105(3):687-96.
• [40]Sousa AR, Poston RN, Lane SJ, Nakhosteen JA, Lee TH: Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev Respir Dis 1993, 147(6 Pt 1):1557-61.
• [41]Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM: Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995, 151(6):1915-24.
• [42]Yamashita N, Tashimo H, Ishida H, Kaneko F, Nakano J, Kato H, et al.: Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol 2002, 219(2):92-7.
• [43]Anticevich SZ, Hughes JM, Black JL, Armour CL: Induction of human airway hyperresponsiveness by tumour necrosis factor-alpha. Eur J Pharmacol 1995, 284(1-2):221-5.
• [44]Thomas PS, Yates DH, Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995, 152(1):76-80.
• [45]Moore KW, de Waal R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
• [46]Schandene L, Alonso-Vega C, Willems F, Gerard C, Delvaux A, Velu T, et al.: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994, 152(9):4368-74.
• [47]Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M: Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. Journal of Experimental Medicine 1994, 180(2):711-715.
• [48]John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, et al.: Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998, 157(1):256-62.
• [49]Stelmach I, Jerzynska J, Kuna P: A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 2002, 32(2):264-9.
• [50]Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S: Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996, 97(6):1288-96.
• [51]Sousa A, Lane S, Nakhosteen J, Lee T, Poston R: Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996, 154(4):1061-1066.
• [52]Yoshida S, Hashimoto S, Nakayama T, Kobayashi T, Koizumi A, Horie T: Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma. Clin Exp Immunol 1996, 106(1):73-8.
• [53]Watson ML, Smith D, Bourne AD, Thompson RC, Westwick J: Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist. Am J Respir Cell Mol Biol 1993, 8(4):365-9.
• [54]Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston RN, et al.: Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. Thorax 1997, 52(5):407-10.
• [55]Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1043-51.
• [56]Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R, et al.: Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003, 167(5):751-7.
• [57]Brannan JD, Koskela H, Anderson SD, Chan HK: Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology 2002, 7(1):37-44.
• [58]Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, et al.: A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997, 156(3 Pt 1):758-65.
• [59]Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14(4):902-7.
• [60]Bewig B, Barth J: Inhibitory effects of inhaled flunisolide on inflammatory functions of alveolar macrophages. Eur J Clin Pharmacol 1993, 44(6):541-4.
• [61]Lipworth BJ, Sims EJ, Das SK, Buck H, Paterson M: Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol 2005, 94(6):675-81.
• [62]Viksman MY, Liu MC, Bickel CA, Schleimer RP, Bochner BS: Phenotypic analysis of alveolar macrophages and monocytes in allergic airway inflammation. I: Evidence for activation of alveolar macrophages, but not peripheral blood monocytes, in subjects with allergic rhinitis and asthma. Am J Respir Crit Care Med 1997, 155(3):858-63.
• [63]Alexis NE, Soukup J, Nierkens S, Becker S: Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am J Physiol Lung Cell Mol Physiol 2001, 280(2):L369-75.
• [64]Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, et al.: Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005, 172(8):972-9.
• [65]Nomura H, Sato E, Koyama S, Haniuda M, Kubo K, Nagai S, et al.: Histamine stimulates alveolar macrophages to release neutrophil and monocyte chemotactic activity. J Lab Clin Med 2001, 138(4):226-35.
• [66]Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ: Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000, 15(4):764-70.
• [67]Cotter TP, Hood PP, Costello JF, Sampson AP: Exposure to systemic prednisolone for 4 hours reduces ex vivo synthesis of GM-CSF by bronchoalveolar lavage cells and blood mononuclear cells of mild allergic asthmatics. Clin Exp Allergy 1999, 29(12):1655-62.
• [68]Linden M, Brattsand R: Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. Pulm Pharmacol 1994, 7(1):43-7.
• [69]Vecchiarelli A, Siracusa A, Cenci E, Puliti M, Abbritti G: Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma. Clin Exp Allergy 1992, 22(3):365-70.
• [70]Nakamura Y, Ozaki T, Kamei T, Kawaji K, Banno K, Miki S, et al.: Increased granulocyte/macrophage colony-stimulating factor production by mononuclear cells from peripheral blood of patients with bronchial asthma. Am Rev Respir Dis 1993, 147(1):87-91.
• [71]Lai CK, Ho SS, Chan CH, Leung R, Lai KN: Gene expression of interleukin-3 and granulocyte macrophage colony-stimulating factor in circulating CD4+ T cells in acute severe asthma. Clin Exp Allergy 1996, 26(2):138-46.
• [72]Wang JH, Trigg CJ, Devalia JL, Jordan S, Davies RJ: Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. J Allergy Clin Immunol 1994, 94(6 Pt 1):1025-34.
• [73]Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, et al.: Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994, 150(1):17-22.
• [74]Amrol DJ, Hagaman DD, Sheller JR, Murray JJ: Soluble CD23 and interleukin-1 receptor antagonist in human asthmatics following antigen challenge. J Asthma 2005, 42(1):73-6.
• [75]Colavita AM, Hastie AT, Musani AI, Pascual RM, Reinach AJ, Lustine HT, et al.: Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. J Allergy Clin Immunol 2000, 106(5):880-6.
• [76]Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al.: Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997, 155(6):1864-71.
• [77]Capraz F, Kunter E, Cermik H, Ilvan A, Pocan S: The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung 2007, 185(2):89-96.
• [78]Hoshino M, Nakamura Y, Sim JJ, Yamashiro Y, Uchida K, Hosaka K, et al.: Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998, 28(5):568-77.
• [79]Hoshino M, Takahashi M, Takai Y, Sim J: Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999, 104(2 Pt 1):356-63.
• [80]Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA: Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997, 156(3 Pt 1):951-8.
• [81]Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier MC, Martel S, et al.: Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med 2000, 162(4 Pt 1):1308-13.
• [82]Hoshino M, Nakamura Y, Sim JJ, Tomioka H: A comparative study of the effects of ketotifen, disodium cromoglycate, and beclomethasone dipropionate on bronchial mucosa and asthma symptoms in patients with atopic asthma. Respir Med 1998, 92(7):942-50.
• [83]Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, et al.: Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002, 57(4):309-16.
• [84]Ward C, Reid DW, Orsida BE, Feltis B, Ryan VA, Johns DP, et al.: Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy 2005, 35(12):1565-71.